Delphine S. Tuot; Feng Lin; Michael G. Shlipak; Vanessa Grubbs; Chi-yuan Hsu; Jerry Yee; Vahakn Shahinian; Rajiv Saran; Sharon Saydah; Desmond E. Williams; Neil R. Powe ...

Some non-small-cell lung cancers (NSCLC) have changes in a gene called EGFR. If your NSCLC has these mutations, your doctor likely will recommend treatment with targeted therapies that block EGFR.

Tagrisso significantly improves overall survival in unresectable stage 3 EGFR-mutant NSCLC, surpassing placebo in the LAURA study. The FDA approved Tagrisso in September 2024 for patients with locally ...

Comprehensive biomarker testing can identify EGFR or other mutations in your lung cancer. Learn the benefits of testing and how it can help shape treatment.